HCV-related liver transplantation and post-transplant survival rates in Europe have improved rapidly in the era of direct-acting antiviral drugs
13 April 2018, Paris, France: HCV-related liver transplantation rates in Europe have declined dramatically since the availability of direct-acting antiviral (DAA) drugs and survival rates after transplantation have reached an all-time high. A study presented today at The International Liver Congress™ 2018 in Paris, France, has found that the percentage of liver transplants performed as a result of hepatitis C virus (HCV) infection has more than halved since the availability of DAA drugs, and that post-transplant survival rates among those with HCV infection are now similar to those reported in patients with hepatitis B virus (HBV) infection.
'Direct-acting antiviral drugs have revolutionized the treatment of HCV-infected individuals – even those with advanced liver disease',1 explained Dr Giovanni Perricone from the ASST Great Metropolitan Hospital Niguarda in Milan, Italy, who presented the study findings today. 'Unlike the older HCV treatment regimens involving ribavirin and pegylated interferon, these newer agents are highly effective and well tolerated across genotypes, and we have shown previously that the remarkable clinical improvements that can be achieved using these agents can lead to the delisting of some individuals waiting for liver transplantation'.2
In the latest research conducted by Dr Perricone and colleagues, data from the European Liver Transplant Registry from between January 2007 and June 2017 were reviewed, involving a total of 36,382 adults who underwent liver transplantation as a result of HCV, HBV, alcoholic liver disease or non-alcoholic steatohepatitis (NASH). To assess the impact of DAAs on liver transplantation rates, data were analyzed in separate treatment eras: the interferon (IFN) era from 2007 to 2010, the protease inhibitor (PI) era from 2011 to 2013, and the second-generation DAA era from 2014 to June 2017.
The percentage of liver transplants conducted as a result of HCV infection decreased from 22.8% during the IFN era to 10.6% during the DAA era. In contrast, the percentage of transplants conducted as a result of NASH increased from 1.1% to 6.2%. Within the DAA era, the percentage of liver transplants due to HCV decreased from 21.1% during the first half of 2014 to 10.6% during the first half of 2017.
According to Dr Perricone, the decreased requirement for liver transplantation during the DAA era was more pronounced in patients with HCV related to decompensated liver disease (-68.8%) than in those with HCV-related hepatocellular carcinoma (-34.0%). The 3-year survival of liver transplant recipients with HCV infection has also improved from 65.1% in the IFN era to 76.9% in the DAA era – a survival rate that is now comparable to that of patients with HBV infection (78.0%) (p=0.38).
'Our study provides clear evidence that DAAs are changing the epidemiology of liver transplantation, at least in countries like Italy where the prevalence of HCV infection is high',3 said Dr Perricone. 'We anticipate that rates of HCV-related transplantation will continue to decline as more patients gain access to these highly effective treatments'.
'For the first time in many years, we have also seen improved survival in liver transplant recipients with HCV infection, and this can be attributed directly to the availability of DAA drugs'.
'These are very important data that emphasize the effectiveness of DAA therapies against HCV', said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. 'These data are important, especially as a recent Cochrane report has concluded that there is not sufficient evidence to understand how sustained virological response affects long-term clinical outcomes'.
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2018 will take place from 11¬-15 April 2018 at the Paris Convention Centre, Paris, France.
About The European Association for the Study of the Liver (EASL)
Since its foundation in 1966, this not-for-profit organization has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
For more information, please contact the ILC Press Office at:
- Email: [email protected]
- Telephone: +41 (0) 22 807 29 88
Onsite location reference
Session title: Poster Late Breakers
Time, date and location of session: 12. April 2018, 09:00 AM – 05:00 PM, Poster Area
Presenter: Giovanni Perricone
Abstract: The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while survival after transplantation is improving: A study based on European Liver Transplant Registry (5412)
1. Gadiparthi C, et al. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol. 2018;24(3):315-22.
2. Belli LS, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65(3):524-31.
3. Viganò R, et al. Change of liver transplantation list composition: pre versus post direct-acting antivirals era. The Niguarda Hospital experience. Dig Liver Dis. 2017;49(3):317.